Back to search
FDAFDA · Food and drugs·Recall number D-0486-2021

Triumeq (abacavir, dolutegravir, and lamivudine) 600 mg/50 mg/300 mg Tablets 30 Tablets Rx Only NDC 49702-231-13 Manufactured for: Viiv Healthcare Research Triangle Park, NC 27709 by GlaxoSmithKline Research Triangle Park, NC 27709

Published June 2, 2021 · Recall initiated: March 15, 2021

Summary

FDA records drug Class II recall D-0486-2021, published June 2, 2021 and initiated March 15, 2021. Recalling firm: Cardinal Health Inc.; Status: Terminated; Reported quantity: 2264 bottles; Lot: GS5G. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

What to do

Voluntary: Firm initiated · Letter

Get an email if TRIUMEQ has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
TRIUMEQ
Manufacturer
Cardinal Health Inc.
Distributor
FL, GA, SC
UPC
0349702231139
Lot
GS5G
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Triumeq (abacavir, dolutegravir, and lamivudine) 600 mg/50 mg/300 mg Tablets 30 Tablets Rx Only NDC 49702-231-13 Manufactured for: Viiv Healthcare Research Triangle Park, NC 27709 by GlaxoSmithKline Research Triangle Park, NC 27709 recalled?

Yes. FDA published recall D-0486-2021 on June 2, 2021. Reported hazard: CGMP Deviations: Intermittent exposure to temperature excursion during storage.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: TRIUMEQ. UPC: 0349702231139.